ArticleFrontiers in cellular neuroscience2021
Brain Metabolite, N-Acetylaspartate Is a Potent Protein Aggregation Inhibitor.
Article in Frontiers in cellular neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- The Emerging Role of N-Acetylaspartate in Cancer.International journal of molecular sciences · 2026Review
- The complex relationship between endocrine and psychiatric disorders: an epidemiological study of risk estimates.Medicine and pharmacy reports · 2026Article
- Aspartate in the Brain: A Review.Neurochemical research · 2025Review
- Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.Journal of extracellular vesicles · 2025Article
- Multiomics Characterization of a Less Invasive Microfluidic-Based Cell Sorting Technique.Journal of proteome research · 2024Article
- Article
- Exploring the Association between Cathepsin B and Parkinson's Disease.Brain sciences · 2024Article
- Microbiota-gut-liver-brain axis and hepatic encephalopathy.Microbiome research reports · 2024Review
- Serum neurotransmitter analysis of motor and non-motor symptoms in Parkinson's patients.Frontiers in aging neuroscience · 2024Article
- Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.Molecular neurobiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deposition of toxic protein inclusions is a common hallmark of many neurodegenerative disorders including Alzheimer's disease, Parkinson disease etc. N-acetylaspartate (NAA) is an important brain metabolite whose levels got altered under various neurodegenerative conditions. Indeed, NAA has been a widely accepted biological marker for various neurological disorders. We have also reported that NAA is a protein stabilizer. In the present communication, we investigated the role of NAA in modulating the aggregation propensity on two model proteins (carbonic anhydrase and catalase). We discovered that NAA suppresses protein aggregation and could solubilize preformed aggregates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.